Core Viewpoint - The approval of GPN01530 by the FDA marks a significant milestone for the company in the global development of radiopharmaceuticals for cancer diagnosis and treatment [1] Group 1: Product Development - The company has received FDA approval to conduct Phase I/II clinical trials for its self-developed radiopharmaceutical GPN01530, aimed at diagnosing solid tumors [1] - GPN01530 is the first self-developed RDC product from the company to gain FDA approval for clinical research, highlighting the company's capabilities in the field of nuclear medicine [1] Group 2: Strategic Initiatives - The company plans to leverage a "dual submission" international registration pathway between China and the U.S. to advance the global research and registration of GPN01530 [1] - The successful approval of GPN01530 is expected to enhance the company's global development strategy in the nuclear medicine sector and promote further international clinical research and registration of innovative self-developed nuclear drugs [1] Group 3: Competitive Positioning - The company aims to strengthen its core competitiveness and international influence in the field of nuclear medicine for cancer diagnosis and treatment through the ongoing development of its product pipeline [1]
远大医药(00512)：自主研发的重磅全球创新放射性核素偶联药物 GPN01530 在美国获批开展临床研究